Diagnostics are a critical part of precision medicine. They can be used to screen patients for breakthrough therapies, detect certain conditions, especially cancer, earlier. But this area of medical innovation is balanced between promising new developments in molecular diagnostics, genetic testing and liquid biopsies, the delivery of these tests, and the all important question of who pays for it.
More than 80% of representatives of health systems have established genomic data management strategies or plan to do so within the next couple of years, according to a report by University of Pittsburgh Medical Center’s Center for Connected Medicine and HIMSS Media, which surveyed 101 health system and hospital representatives in the U.S. The report indicated that health systems anticipate growth and increased use of genomics. Evidence of clinical and cost effectiveness and reimbursement are crucial for wider adoption of precision medicine programs.
Although the development and distribution of tests to diagnose COVID-19 has dominated much of the news this year, there has also been much activity in the way of development of molecular diagnostic tests and liquid biopsies.
Advanced diagnostic tests can stratify patients for response, non-response, and adverse events to costly therapies and interventions that do not yield improvement or positive outcome for patients.
In this eBook, we offer a look at some of the promising diagnostic developments and trends in this area, tempered by the need to make financing considerations an essential part of the conversation.
Please fill out the form below to download the eBook, The Diagnostics Chapter of Precision Medicine.
Photo: Natali_Mis, Getty Images